BPC-157 vs TB-500
A synthetic peptide with broad preclinical repair claims and little human data. A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
BPC-157 | TB-500 | |
|---|---|---|
| Also known as | — | — |
| Type | Research | Research |
| Evidence | Preclinical | Preclinical |
| Family | Repair & regenerative | Repair & regenerative |
| Class | Synthetic pentadecapeptide (15 aa) | Synthetic thymosin β4 fragment / analog |
| Receptor | No established receptor; proposed effects on angiogenesis and growth-factor pathways | Same actin-related biology as thymosin β4 (not receptor-mediated) |
| Molecular weight | ~1,419.5 Da | — |
| Half-life | Poorly characterized in humans | Poorly characterized in humans |
| Based on | Native hormone | Thymosin β4 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between BPC-157 and TB-500?
- BPC-157 is a research peptide; TB-500 is a research peptide based on Thymosin β4. BPC-157 signals at No established receptor; proposed effects on angiogenesis and growth-factor pathways; TB-500 signals at Same actin-related biology as thymosin β4 (not receptor-mediated).
- How do the half-lives of BPC-157 and TB-500 compare?
- The reported circulating half-life of BPC-157 is Poorly characterized in humans; TB-500 is Poorly characterized in humans. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? TB-500 vs BPC-157. Or open the interactive comparison tool to add more molecules.